A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

被引：0
|
作者：
Takeo Fujii
Hiroko Masuda
Yee Chung Cheng
Fei Yang
Aysegul A. Sahin
Yasuto Naoi
Yuki Matsunaga
Akshara Raghavendra
Arup Kumar Sinha
Jose Rodrigo Espinosa Fernandez
Anjali James
Keisuke Yamagishi
Tomoko Matsushima
Robert Schuetz
Debu Tripathy
Sachiyo Tada
Rubie S. Jackson
Shinzaburo Noguchi
Seigo Nakamura
Jared D. Acoba
Naoto T. Ueno
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Breast Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354
[3] University of Hawai’i,John A. Burns School of Medicine
[4] University of Hawai’i Cancer Center,Department of Breast Surgical Oncology
[5] Showa University,Division of Hematology and Oncology
[6] Medical College of Wisconsin,Department of Translational Molecular Pathology
[7] The University of Texas MD Anderson Cancer Center,Department of Pathology
[8] The University of Texas MD Anderson Cancer Center,Department of Breast and Endocrine Surgery
[9] Osaka University Graduate School of Medicine,Anne Arundel Medical Center
[10] Sysmex Corporation,undefined
[11] Rebecca Fortney Breast Center,undefined
[12] Hyogo Prefectural Nishinomiya Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 189卷
关键词：
Breast cancer; 21-gene signature assay; 95-gene signature assay; Estrogen receptor-positive; Recurrence Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：455 / 461
页数：6
相关论文
共 50 条
  • [21] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Turashvili, Gulisa
    Chou, Joanne F.
    Brogi, Edi
    Morrow, Monica
    Dickler, Maura
    Norton, Larry
    Hudis, Clifford
    Wen, Hannah Y.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 69 - 76
  • [22] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Gulisa Turashvili
    Joanne F. Chou
    Edi Brogi
    Monica Morrow
    Maura Dickler
    Larry Norton
    Clifford Hudis
    Hannah Y. Wen
    [J]. Breast Cancer Research and Treatment, 2017, 166 : 69 - 76
  • [23] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [24] A retrospective study of 21-gene recurrence score assay compared with clinicopathological markers in node-negative, hormone receptor-positive, HER2-negative breast cancer.
    Chen, Junqing
    Wang, Xiaojia
    Chen, Zhanhong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer
    Holowatyj, Andreana N.
    Cote, Michele L.
    Ruterbusch, Julie J.
    Ghanem, Kristina
    Schwartz, Ann G.
    Viguerm, Fawn D.
    Gorski, David H.
    Purrington, Kristen S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 652 - +
  • [26] Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay
    Ahn, Sung Gwe
    Bae, Soong June
    Yoon, Changik
    Cha, Yoon Jin
    Lee, Hak Woo
    Lee, Seung Ah
    Jeong, Joon
    [J]. PLOS ONE, 2017, 12 (11):
  • [27] Chemosensitivity of ER-positive/HER2-negative breast cancers with higher 21-gene recurrence score (≥ 26): a study based on in vitro chemoresponse assay
    Ahn, S. G.
    Lee, H. W.
    Lim, J. W.
    Baek, S. H.
    Bae, S. J.
    Yoon, C.
    Cha, Y. J.
    Jeong, J.
    [J]. BREAST, 2017, 32 : S88 - S88
  • [28] Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    Lamond, Nathan W. D.
    Skedgel, Chris
    Rayson, Daniel
    Lethbridge, Lynn
    Younis, Tallal
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1115 - 1123
  • [29] Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    Nathan W. D. Lamond
    Chris Skedgel
    Daniel Rayson
    Lynn Lethbridge
    Tallal Younis
    [J]. Breast Cancer Research and Treatment, 2012, 133 : 1115 - 1123
  • [30] The 70-gene signature (70-GS) in a lymph node-negative patient series with intermediate risk 21-gene recurrence scores (RS) and known adjuvant treatment recommendations
    Lo, S. S.
    Mai, H.
    McCroskey, Z.
    Guo, R.
    Ersahin, C.
    Gaynor, E. R.
    Robinson, P. A.
    Albain, K. S.
    [J]. CANCER RESEARCH, 2013, 73
12345